Long-term survival of 106 stage III ovarian cancer patients with minimal residual disease after second-look laparotomy and consolidation radiotherapy

6046 Background: The role of intraperitoneal (IP) chemotherapy in the management of advanced ovarian cancer has been questioned given emerging evidence showing lack of survival benefits. The objective of this study was to compare the long-term survival associated with IP chemotherapy at a tertiary cancer center. Methods: We reviewed the long-term survival records of 271 women with stage IIIC or IV high-grade serous ovarian cancer treated with primary cytoreductive surgery (PCS) followed by IP or intravenous (IV) chemotherapy between 2001-2015 with a minimum follow-up of 4 years. 5-year progression free (PFS) and overall survival (OS) rates were compared using Kaplan-Meier survival analysis and covariates were evaluated using Cox regression analysis. Results: Women who received IP chemotherapy after PCS (n = 91) were more likely to have undergone aggressive surgery (p < 0.001), longer surgery (p < 0.001), and had no residual disease (p < 0.001) compared to the IV arm (n = 180). Median follow-up was 51.6 months. Five-year PFS was 19% vs. 18% (p = 0.63) and OS was 73% vs. 44% (p = 0.00016) in the IP vs. IV arms, respectively. After controlling for covariates in a multivariable model, the use of IP was no longer a significant predictor of OS in the entire cohort (p = 0.12). In patients with 0mm residual disease, PFS was 28% vs. 26% (p = 0.67) and OS was 81% vs. 60% (p = 0.059) in IP (n = 61) vs. IV (n = 69), respectively. In patients with residual of 1-9mm, PFS was 30% vs. 48% (p = 0.076) and OS was 60% vs. 43% (p = 0.74) in IP (n = 29) vs. IV (n = 31), respectively. Conclusions: IP chemotherapy showed a trend towards improved survival over conventional IV chemotherapy, especially in patients with no residual disease. Given the retrospective nature and small numbers in this study, prospective non-randomized cohort studies are warranted to evaluate the role of IP chemotherapy in advanced ovarian cancer.

Download Full-text

Abstract GMM-057: A FUNCTIONAL HOMOLOGOUS RECOMBINATION ASSAY PREDICTS PRIMARY CHEMOTHERAPY RESPONSE AND LONG-TERM SURVIVAL IN OVARIAN CANCER PATIENTS

10.1158/1557-3265.ovcasymp18-gmm-057 ◽

2019 ◽

Author(s):

Manuela Tumiati ◽

Sakari Hietanen ◽

Johanna Hynninen ◽

Elina Pietilä ◽

Anniina Färkkilä ◽

...

Keyword(s):

Ovarian Cancer ◽

Homologous Recombination ◽

Cancer Patients ◽

Primary Chemotherapy ◽

Chemotherapy Response ◽

Term Survival ◽

Long Term Survival ◽

Recombination Assay

Download Full-text

Intraperitoneal (ip) Cisplatin-Mitoxantrone-Interferon-α2b in Ovarian Cancer Patients with Minimal Residual Disease

Gynecologic Oncology ◽

10.1006/gyno.1993.1165 ◽

1993 ◽

Vol 50 (1) ◽

pp. 60-67 ◽

Cited By ~ 10

Author(s):

G. Frasci ◽

A. Tortoriello ◽

G. Facchini ◽

S. Conforti ◽

A. Cardone ◽

...

Keyword(s):

Ovarian Cancer ◽

Cancer Patients ◽

Minimal Residual Disease ◽

Residual Disease ◽

Interferon Α2b ◽

Minimal Residual

Download Full-text

Long-term survival in a randomized study of nonplatinum therapy versus platinum in advanced epithelial ovarian cancer

International Journal of Gynecological Cancer ◽

10.1111/j.1525-1438.2007.00862.x ◽

2007 ◽

Vol 17 (5) ◽

pp. 986-992 ◽

Cited By ~ 3

Author(s):

M. O. Nicoletto ◽

S. Tumolo ◽

R. Sorio ◽

G. Cima ◽

L. Endrizzi ◽

...

Keyword(s):

Ovarian Cancer ◽

Overall Survival ◽

Epithelial Ovarian Cancer ◽

Residual Disease ◽

Randomized Study ◽

Disease Free Survival ◽

Term Survival ◽

Long Term Survival ◽

Disease Free

The purpose of this study was to compare long-term survival in first-line chemotherapy with and without platinum in advanced-stage ovarian cancer. From July 1987 to November 1992, 161 untreated patients with FIGO stage III–IV epithelial ovarian cancer were randomized: 81 patients received no platinum and 80 received platinum combination. Residual disease after surgery was <2 cm in 61 patients without platinum, 59 with platinum. Median age was 58 years in nonplatinum arm and 55 years in platinum arm (range: 15–73). Complete and partial responses were 51% and 10% for nonplatinum arm and 51% and 8% for platinum arm, respectively (P= 0.7960). Stable disease was observed in 18% of patients in nonplatinum arm and 15% of patients in platinum arm and progression in 20% of nonplatinum- and 21% of platinum-treated cases. Ten-year disease-free survival was 37% for therapy without platinum and 31% for platinum combination (P= 0.5679); 10-year overall survival was 23% without platinum and 31% with platinum combination (P= 0.2545). Fifteen-year overall survival showed a trend of short duration in favor of platinum (P= 0.0678). Relapses occurred after 60 months in ten patients (seven with and three without platinum). The overall and disease-free survivals at 5, 10, and 15 years show no statistically significant long-term advantage from the addition of cisplatin; however, there is a slight trend in its favor.

Download Full-text

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Blood ◽

10.1182/blood-2015-06-649111 ◽

2015 ◽

Vol 126 (24) ◽

pp. 2578-2584 ◽

Cited By ~ 80

Author(s):

Gerhard Zugmaier ◽

Nicola Gökbuget ◽

Matthias Klinger ◽

Andreas Viardot ◽

Matthias Stelljes ◽

...

Keyword(s):

T Cell ◽

Cell Kinetics ◽

Residual Disease ◽

Lymphoblastic Leukemia ◽

Term Survival ◽

Long Term Survival ◽

Disease Response ◽

Key Points ◽

Minimal Residual

Key Points Ten of 36 patients (28%) achieved an OS ≥30 months in a blinatumomab study in relapsed/refractory acute lymphoblastic leukemia. Long-term survival may be associated with T-cell expansion, B-cell depletion, and a minimal residual disease response.

Download Full-text